Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.78 |
| ▸ | CA1 | P00915 | 1/20 | 0.78 |
| ▸ | CA2 | P00918 | 1/20 | 0.78 |
| ▸ | CA3 | P07451 | 1/20 | 0.78 |
| ▸ | CA4 | P22748 | 1/20 | 0.78 |
| ▸ | CA5A | P35218 | 1/20 | 0.78 |
| ▸ | CA7 | P43166 | 1/20 | 0.78 |
| ▸ | CA9 | Q16790 | 1/20 | 0.78 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.78 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CDC25A | P30304 | 2/20 | 0.54 |
| ▸ | CDC25C | P30307 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28878363 | 0.88 | CA12 (1.00) | CA12CA1CA2CA3CA4 | |
| SCHEMBL6030326 | 0.84 | CA12 (0.68) | CA12CA1CA2CA3CA4 | |
| SCHEMBL6030323 | 0.84 | CA12 (0.68) | CA12CA1CA2CA3CA4 | |
| SCHEMBL28546496 | 0.84 | CA12 (0.72) | CA12CA1CA2CA3CA4 | |
| SCHEMBL6029898 | 0.83 | CA12 (0.67) | CA12CA1CA2CA3CA4 | |
| SCHEMBL15842416 | 0.80 | CA9 (0.50) | CA12CA1CA2CA3CA4 | |
| SCHEMBL3055094 | 0.80 | HSD17B3 (0.63) | CA12CA9KDM4EALDH1A1HPGD | |
| SCHEMBL3911979 | 0.80 | KDM4E (0.69) | CA12CA1CA2CA3CA4 | |
| SCHEMBL246219 | 0.79 | KDM4E (0.62) | CA12CA1CA2CA3CA4 | |
| SCHEMBL14424527 | 0.79 | KDM4E (0.73) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20100048604-A1 | Ligands for Aldoketoreductases | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2010-02-25 | — | — | US | disclosed |
| US-20100048604-A1 | Ligands for Aldoketoreductases | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2010-02-25 | — | — | US | disclosed |
| US-20060105458-A1 | Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression | MAX-PLANCK-GESELLSCHAFT ZUR FODERUNG DER WISSENSCHAFTEN E.V. (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20050267102-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-01 | — | — | US | disclosed |
| US-6911449-B2 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1534839-A1 | CAGED TETRACYCLINE (DERIVATIVES), THEIR GENERATION, AND THEIR USE FOR PHOTOACTIVATED GENE EXPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2005-06-01 | — | — | EP | disclosed |
| EP-0923530-B1 | INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED BIARYL OXOBUTYRIC ACIDS | BAYER AG (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6762184-B2 | RHEUMATIC DISEASES; ORAL ISEASES; VISION DEFECTS; ANTIINFLAMMATORY AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20040127500-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-5932577-A | OSTEOPOROSIS; ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS;NERVOUS SYSTEM DISORDERS; ANTITUMOR AGENTS; CARDIOVASCULAR DISORDERSANTITUMOR AGENTSD | BAYER CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| US-5932763-A | Inhibition of matrix metalloproteases by 2-(ω-arolalkyl)-4-biaryl-4-oxobutyric acids | BAYER CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| US-5925637-A | ENZYME INHIBITORS AS ANTIARTHRITIC AGENTS OR CARDIOVASCULAR DISORDERS | BAYER CORPORATION (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0923529-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | Bayer Corporation (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0907632-A1 | INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED PHENETHYL COMPOUNDS | Bayer Corporation (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5863915-A | ENZYME INHIBITORS FOR BONES AND JOINTS | BAYER CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| US-5804581-A | ADMINISTERING ENZYME INHIBITOR TO TREAT OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISORDERS, CORNEAL ULCERATION, PROTEINURIA, OSTEOPENIAS, DYSTROPHY, CORONARY THROMBOSIS, TUMOR METASTASIS AND BULLOSA | BAYER CORPORATION (US) | 1998-09-08 | — | — | US | disclosed |
| WO-1998022436-A1 | SUBSTITUTED 4-BIPHENYL-4-HYDROXYBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1997043247-A1 | INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED PHENETHYL COMPOUNDS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997043237-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127500-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | ADAMTS5, ADAMTS1, MMP26 | CA12 580/4885CA1 250/4885CA2 178/4885 |
| US-20100048604-A1 | Ligands for Aldoketoreductases | AKR1C2, AKR1C1, AKR1B1 | CA12 4661/4885CA1 4678/4885CA2 4465/4885 |
| US-20060105458-A1 | Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression | TET1, TEAD2, MYC | CA12 4516/4885CA1 4413/4885CA2 3812/4885 |
| US-20050267102-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | MMP20, ADAMTS5, MMP10 | CA12 477/4885CA1 250/4885CA2 180/4885 |
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | CA12 2098/4885CA1 2450/4885CA2 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.